Cardax (QB) Stock Price

0.00 (0.0%)
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cardax Inc (QB) CDXI OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 2.25 0.00 0.00 0.00 2.25 20:00:00
Bid Price Ask Price Spread Spread % News
0.0001 3.75 3.75 100.0% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.25 USD

Cardax (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.67M 744.32k 278.15k $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
25.00 $ - 0.00% - -

more financials information »

Cardax (QB) News

Date Time Source News Article
5/15/202016:39Edgar (US Regulatory)Quarterly Report (10-q)
5/15/202016:02Edgar (US Regulatory)Current Report Filing (8-k)
3/30/202007:49Edgar (US Regulatory)Annual Report (10-k)
3/20/202017:08Edgar (US Regulatory)Current Report Filing (8-k)
1/27/202017:09Edgar (US Regulatory)Current Report Filing (8-k)
12/06/201917:28Edgar (US Regulatory)Current Report Filing (8-k)
11/22/201916:05Edgar (US Regulatory)Securities Registration Statement (s-1/a)
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CDXI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month4.504.502.002.86888-2.25-50.0%
3 Months6.7515.002.005.08571-4.50-66.67%
6 Months0.05515.000.045051.481,8352.203,990.91%
1 Year0.100115.000.0320.112353730,4172.152,147.75%
3 Years0.199915.000.0320.215266542,2722.051,025.56%
5 Years0.11515.000.030.193655446,5902.141,856.52%

Cardax (QB) Description

Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. The Company also has a commercial business unit that markets ZanthoSyn, a physician recommended astaxanthin dietary supplement for inflammatory health. CDX-101, the Company's astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company's zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. The Company's pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. The safety and efficacy of the Company's pharmaceutical candidates have not been directly evaluated in clinical trials or confirmed by the FDA.
Your Recent History
Cardax (QB..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200708 10:56:34